Press Releases Genmab A/S Xetra

Equities

GE9

DK0010272202

Real-time Estimate Tradegate Other stock markets 06:46:28 2024-05-29 am EDT			5-day change	1st Jan Change
258.6 ^EUR	-21.89%		0.00%	0.00%

May. 21	Genmab A/S Reaffirms Financial Guidance for 2024	CI
May. 21	Genmab A/S completed the acquisition of ProfoundBio, Inc.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transactions in Connection with Share Buy-back Program	May. 27	GL
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting	May. 23	BU
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting	May. 23	GL
Genmab Completes Acquisition of ProfoundBio	May. 21	BU
Genmab Completes Acquisition of ProfoundBio	May. 21	GL
Transactions in Connection with Share Buy-back Program	May. 21	GL
Legal Limbo: Genmab's Ofatumumab SPC Dilemma Heads To CJEU	May. 20	AQ
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	May. 14	BU
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	May. 14	GL
Transactions in Connection with Share Buy-back Program	May. 13	GL
Genmab A/S : has published its Articles of Association	May. 08	PU
Genmab A/S : Articles of association dated May 07, 2024 – English	May. 08	PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise	May. 07	GL
Transactions in Connection with Share Buy-back Program	May. 06	GL
Genmab A/S : Investor Presentation - May 2024	May. 02	PU
Genmab A/S : Interim Report for the First Quarter of 2024	May. 02	PU
Genmab A/S : First Quarter 2024 Financial Results Presentation	May. 02	PU
Genmab Announces Financial Results for the First Quarter of 2024	May. 02	GL
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	GL
Transactions in Connection with Share Buy-back Program Genmab	Apr. 29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT